Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients

Table 2 Clinicopathological features of the 29 HNSCC patients on the UPCI 08-013 trial

Patient	Gender	Age	Tumor site	T-stage, clinical	N-stage, clinical	M-stage, clinical	T-stage, path	N-stage, path	M-stage, path	HPV status
1	Male	31	OC	T3	N0	M0	T2	N1	M0	-
2	Male	51	OC	T4	N1	M0	T4A	N0	M0	-
3	Male	48	OP	T2	N2	M0	T3	N2B	MX	+
4	Female	68	OC	T4A	N1	M0	T4A	N0	MX	+
5	Male	62	OP	T1	N1	M0	T1	N2A	MX	+
6	Male	69	OP	T2	N2	M0	T3	N2B	MX	+
7	Female	75	OC	T4	N0	M0	T4A	N0	MX	-
8	Male	65	OC	T2	N2	M0	T1	N2A	MX	-
9	Male	49	OP	T1	N2B	M0	T2	N1	MX	+
10	Female	40	OC	T2	N2B	M0	T2	N2B	MX	-
11	Female	58	OC	T3	N2B	M0	T2	N2B	MX	-
12	Female	83	OC	T4A	N0	M0	T4A	N0	MX	-
13	Male	55	L	T3	N1	M0	T3	N1	MX	-
14	Male	64	OC	T1	N1	M0	T1	N1	MX	-
15	Female	51	OP	T4	N0	M0	T2	N0	MX	-
16	Male	59	OP	T2	N2B	M0	T2	N2A	MX	+
17	Male	64	OP	T2	N1	M0	T2	N2B	MX	+
18	Male	62	OC	T2	N0	M0	TX	N0	MX	-
19	Male	54	OC	T2	N2C	M0	T2	N2C	MX	-
20	Male	62	OC	T4	N1	M0	T2	N1	MX	-
21	Male	93	OC	T4A	N0	M0	TX	NX	MX	-
22	Male	58	OP	T2	N1	M0	T3	N1	MX	-
23	Female	47	OC	T4A	N1	M0	T4A	N1	MX	-
24	Male	59	OC	T4A	N0	M0	T4A	N0	MX	-
25	Male	64	OP	T2	N1	M0	T1	N1	MX	+
26	Male	43	OP	T2	N2B	M0	T2	N2B	MX	+
27	Female	74	L	T4	N1	M0	T3	N2C	MX	-
28	Female	57	OC	T4A	N1	M0	T2	N1	MX	-
29	Male	57	OP	T3	N2B	M0	T1	N0	MX	+